Last month, Gilead Sciences CEO Daniel O’Day announced plans to introduce 10 “transformative medicines” over the next 10 years. Acquisitions would help meet that ambitious goal, and this week Gilead announced... Read more »
A 20-patient Phase 1 study of an RNA drug discovered by Ionis Pharmaceuticals that is being tested as a treatment for Huntington’s disease by Roche was suspended after two reports of... Read more »
Cell therapies have helped treat some blood cancers, but toxic side effects are one limitation preventing their use in solid tumors.
Amunix has, since its 2006 launch, licensed to biopharmas technology... Read more »
The FDA on Monday approved a Sanofi antibody drug for adults with multiple myeloma whose disease hasn’t responded to at least two prior therapies, including the chemotherapy lenalidomide and a proteasome... Read more »
With one investigational cancer drug in Phase 1 testing and a second one approaching the clinic, ORIC Pharmaceuticals is looking to tap the public markets for funds to finance that research.... Read more »
Biogen is opening up its checkbook again to get its hands on innovative approaches to some brain disorders that have proven especially recalcitrant to new types of treatment.
The Cambridge, MA-based... Read more »
Gene therapy developer Passage Bio priced its initial public offering at $18 per share, raising $216 million—72 percent more than it originally planned to raise.
Earlier this month Passage filed to... Read more »
An investigational antiviral drug Gilead Sciences has been developing to treat infections caused by the Ebola virus will be tested in about 1,000 adults diagnosed with COVID-19, the novel coronavirus that... Read more »
About three years ago fledgling San Diego-based startup PvP Biologics announced a $35 million deal with Takeda Pharmaceutical that gave the Japan pharma giant rights to acquire the company down the... Read more »
In what looks to be a transformative year for potential treatments of nonalcoholic steatohepatitis, the liver disease better known as NASH, another biotech has revealed that its experimental drug appears to... Read more »
The price of insulin, a life-saving treatment discovered a century ago, has been a flashpoint amid the broader drug pricing debate. The FDA is trying to tame high insulin prices by... Read more »
Since a major restructuring at Five Prime Therapeutics in October that kicked off a wind-down of most of its research and preclinical efforts, the company has been looking to add to... Read more »
Many companies are working to develop new drugs that target harmful proteins associated with neurodegenerative diseases.
EnClear Therapies has raised a $10 million Series A round of financing from a syndicate... Read more »
A Teva Pharmaceutical drug in testing as a treatment for tics in pediatric patients with moderate-to-severe Tourette syndrome has failed two late-stage trials.
Israel-based Teva (NYSE: TEVA) said Wednesday that... Read more »
A year ago Five Prime Therapeutics cut a fifth of its workforce to save money as its worked to advance its clinical-stage drugs for solid tumor cancers.
On Tuesday the company... Read more »
The president’s State of the Union address was wide-ranging, as they tend to be, but those who tuned in heard mention of two hot health policy topics: price transparency and drug... Read more »
Scripps Research is charting new territory with its Calibr division, a drug discovery and drug development group within the research institute that is advancing its own experimental treatments.
This week Calibr... Read more »
Gene editing biotech Beam Therapeutics raised $180 million in its initial public offering Wednesday after offering 48 percent more shares than it initially anticipated.
Beam, which was slated to begin trading... Read more »
To have a therapeutic effect, drugs need to bind to proteins. But since it isn’t always possible to find an appropriate receptor, Coda Biotherapeutics is designing receptors, which it plans to... Read more »
Last week the FDA approved an Aimmune Therapeutics drug for children with peanut allergies, the first oral immunotherapy for a food allergy to get the agency’s nod.
On Wednesday the... Read more »